Mutability and relationship between positive and negative symptoms during neuroleptic treatment in schizophrenia

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/28518/1/0000315.pd

Cholinergic mechanisms in schizophrenia: Relationship to sleep-EEG abnormalities and positive/ negative symptoms

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/30875/1/0000539.pd

Cholinergic mechanisms and REM sleep abnormalities in schizophrenia

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/30304/1/0000706.pd

Sleep onset REM periods in schizophrenic patients

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/29224/1/0000279.pd

Muscarinic cholinergic hyperactivity in schizophrenia : relationship to positive and negative symptoms

Based on the implication of increased muscarinic ACh activity in the production of negative symptoms, the association of decreasing cholinergic activity with positive symptoms, and the covariance of positive and negative symptoms in the psychotic phase of schizophrenia, a model of (DA) dopaminergic/(ACh) cholinergic interactions in schizophrenia was recently formulated. It suggests that DA/ACh balance is of central importance in schizophrenic pathophysiology and that muscarinic ACh activity increases in an attempt to maintain this balance in the face of increasing DA activity that occurs in the psychotic phase of the illness. The model further suggests that the muscarinic system exerts a damping influence on the emergence of positive symptoms associated with DA hyperactivity, but that this compensatory increase in muscarinic activity is accompanied by an intensification of negative symptoms. In the present study, we tested two important postulates of this model. We tested the prediction that muscarinic activity is increased in schizophrenia by comparing the effect of biperiden, an antimuscarinic M-1 agent, on REM latency in 12 drug-free schizophrenic inpatients and matched normal controls. We found that biperiden caused a smaller increase in REM latency in schizophrenic patients, suggesting that muscarinic activity is increased in schizophrenia. We tested the prediction that an anticholinergic agent would increase positive symptoms and decrease negative symptoms by studying the effect of 8 mg of biperiden/day for 2 days on positive and negative symptoms (assessed by the BPRS) in 30 medication-free schizophrenic inpatients. Biperiden produced a significant increase in positive symptoms (t = 6.36, DF = 29, P t = -2.05, DF = 29, P < 0.05). These findings suggest that central muscarinic activity is increased in the psychotic phase of schizophrenia and is relevant to the expression of positive and negative symptoms.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/29522/1/0000609.pd

Natural killer cell activity in depressive illness: preliminary report

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/27710/1/0000096.pd

Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: A replication

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/30564/1/0000197.pd

Positive and negative symptoms in schizophrenia and the dexamethasone suppression test

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/28016/1/0000452.pd